NEW YORK – Generex Biotechnology, a biopharma and diagnostics firm based in Miramar, Florida, today said that it has signed a letter of intent to acquire immunotherapy firm Kiromic.
Generex said that it intends to merge Kiromic with a newly formed entity, called NuGenerex Immuno-Oncology, that will contain the operations of both Kiromic and Generex subsidiary Antigen Express, which is developing AE37, an experimental cancer vaccine, in combination with checkpoint inhibitors for treatment of triple negative breast cancer.
Houston, Texas-based Kiromic is developing multiple immune-oncology platforms including CAR-T and CAR NK programs, and has developed a product called Diamond AI, an artificial intelligence system that combines genomic sequencing, proteomic, and clinical data to provide predictive algorithms that may identify tumor mutations that can be targeted with immunotherapy. The firm has multiple oncology-focused collaborations with academic centers including Harvard Medical School, Yale University, and MD Anderson Cancer Center.
Financial terms of the proposed acquisition were not disclosed.